FINWIRES · TerminalLIVE
FINWIRES

NSE:MARKSANS

4 stories mentioning NSE:MARKSANSUpdated 37d ago

Every FINWIRES story that references NSE:MARKSANS, newest first.

Research

Choice Equity Downgrades Marksans Pharma to Add from Buy, Price Target is INR290

BOM:524404NSE:MARKSANS
Asia Markets

Indian Equities Fall as Rising Oil Prices and Global Uncertainty Weigh on Sentiment

Indian benchmark indices closed lower on Tuesday, snapping a two-session winning streak, as weak global cues and a rise in crude oil prices triggered profit booking.The BSE Sensex declined 479.26 points, or 0.6%, to close at 76,009.70, while the NSE Nifty 50 fell 118.00 points, or 0.5%, to settle at 23,913.70.Market sentiment remained cautious after U.S. strikes on Iran reduced expectations of a near-term peace agreement. Reports of military activity in southern Iran pushed crude oil prices higher and added pressure on the Indian rupee.In earnings news, Marksans Pharma (NSE:MARKSANS, BOM:524404) surged 16% after fiscal fourth-quarter consolidated net profit rose to 1.48 billion rupees from 905.5 million rupees a year earlier. Revenue from operations increased to 8.56 billion rupees from 7.08 billion rupees.Adani Green Energy (NSE:ADANIGREEN, BOM:541450) gained over 3% after the company said its step-down subsidiaries operationalized battery energy storage system projects and a solar energy project in Gujarat, India.

^BSENifty 50BOM:524404BOM:541450NSE:ADANIGREENNSE:MARKSANS
Asia

Marksans Pharma's Consolidated Net Profit Jumps in Fiscal Q4; Shares Jump 7%

Marksans Pharma's (NSE:MARKSANS, BOM:524404) consolidated attributable net profit rose to 1.48 billion Indian rupees in the fiscal fourth quarter ended March 31, from 905.5 million rupees a year ago.Earnings per share climbed to 3.27 rupees from 2.00 rupees a year earlier, the pharmaceutical company said in a filing to the Indian stock exchanges on Tuesday.Revenue from operations in fiscal Q4 also increased to 8.56 billion rupees from 7.08 billion rupees a year ago.The company's board recommended a final dividend of 0.90 rupees per equity share of face value of 1 rupee per share for the fiscal year ended March 31.The company's shares were up nearly 7% in recent trade.

BOM:524404NSE:MARKSANS
Asia

Marksans Pharma Board to Consider Dividend for Fiscal 2026

Marksans Pharma (NSE:MARKSANS, BOM:524404) said its board of directors will meet on May 26 to consider the declaration of dividend for the financial year 2025-26, according to a filing with the Indian bourses on Tuesday.

BOM:524404NSE:MARKSANS

Track with the FINWIRES app suite